Literature DB >> 16267363

Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations.

Patrick Mallia1, Sebastian L Johnston.   

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of morbidity, mortality, and rising health care costs. In addition, they are associated with an accelerated loss of lung function and thus have a direct effect on disease progression. There are few studies examining the cellular and molecular mechanisms of COPD exacerbations. Exacerbations are linked to increased airway inflammation and oxidative stress, but many questions remain unanswered regarding the key inflammatory cells and mediators. Current therapies for COPD exacerbations are of limited effectiveness, and a better understanding of the inflammatory events at exacerbation is required to devise new therapeutic agents. The development of experimental models of exacerbation-for example, the use of experimental rhinovirus infection in humans with COPD-would greatly facilitate studies of exacerbations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267363     DOI: 10.1513/pats.200504-025SR

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  13 in total

Review 1.  Animal models of chronic obstructive pulmonary disease.

Authors:  Joanne L Wright; Manuel Cosio; Andrew Churg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-02       Impact factor: 5.464

2.  Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection.

Authors:  Carla M T Bauer; Caleb C J Zavitz; Fernando M Botelho; Kristen N Lambert; Earl G Brown; Karen L Mossman; John D Taylor; Martin R Stämpfli
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

3.  Glutathione Peroxidase-1 Suppresses the Unfolded Protein Response upon Cigarette Smoke Exposure.

Authors:  Patrick Geraghty; Nathalie Baumlin; Matthias A Salathe; Robert F Foronjy; Jeanine M D'Armiento
Journal:  Mediators Inflamm       Date:  2016-12-13       Impact factor: 4.711

Review 4.  Community pharmacy COPD services: what do researchers and policy makers need to know?

Authors:  Michael J Twigg; David J Wright
Journal:  Integr Pharm Res Pract       Date:  2017-02-07

Review 5.  Experimental animal models for COPD: a methodological review.

Authors:  Vahideh Ghorani; Mohammad Hossein Boskabady; Mohammad Reza Khazdair; Majid Kianmeher
Journal:  Tob Induc Dis       Date:  2017-05-02       Impact factor: 2.600

6.  The effects of anti-Fas ribozyme on T lymphocyte apoptosis in mice model with chronic obstructive pulmonary disease.

Authors:  Song-Ming Zhuo; Si-Cong Li; Yong-Qun Lin; Hai-Bin Yu; Na Li
Journal:  Iran J Basic Med Sci       Date:  2017-10       Impact factor: 2.699

7.  The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells.

Authors:  Siân C Piper; John Ferguson; Linda Kay; Lisa C Parker; Ian Sabroe; Matthew A Sleeman; Emmanuel Briend; Donna K Finch
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

8.  Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.

Authors:  Markus P Radsak; Christian Taube; Philipp Haselmayer; Stefan Tenzer; Helmut R Salih; Rainer Wiewrodt; Roland Buhl; Hansjörg Schild
Journal:  Clin Dev Immunol       Date:  2007

9.  Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice.

Authors:  Robert F Foronjy; Abdoulaye J Dabo; Clifford C Taggart; Sinead Weldon; Patrick Geraghty
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Miao Liu; Xianggen Zhong; Yuhang Li; Fengjie Zheng; Ruohan Wu; Yan Sun; Jinchao Zhang
Journal:  BMC Complement Altern Med       Date:  2014-07-11       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.